Transamerica Financial Advisors Inc. Sells 1,527 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Transamerica Financial Advisors Inc. cut its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 44.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,932 shares of the biopharmaceutical company’s stock after selling 1,527 shares during the quarter. Transamerica Financial Advisors Inc.’s holdings in Royalty Pharma were worth $50,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Brooklyn Investment Group increased its holdings in Royalty Pharma by 1,006.9% in the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 876 shares in the last quarter. Allworth Financial LP increased its stake in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 877 shares in the last quarter. Riverview Trust Co lifted its position in shares of Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,186 shares during the period. Fifth Third Bancorp lifted its position in shares of Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 997 shares during the period. Finally, Blue Trust Inc. grew its holdings in Royalty Pharma by 31.3% in the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 376 shares during the period. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $31.37 on Monday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The firm’s 50-day simple moving average is $32.44 and its 200 day simple moving average is $28.86. The stock has a market cap of $18.08 billion, a price-to-earnings ratio of 21.63, a PEG ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, research analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were issued a $0.22 dividend. The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.81%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is currently 60.69%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a report on Friday. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.